IS5375A - KAY-Innovative Immune Protein - Google Patents

KAY-Innovative Immune Protein

Info

Publication number
IS5375A
IS5375A IS5375A IS5375A IS5375A IS 5375 A IS5375 A IS 5375A IS 5375 A IS5375 A IS 5375A IS 5375 A IS5375 A IS 5375A IS 5375 A IS5375 A IS 5375A
Authority
IS
Iceland
Prior art keywords
kay
innovative
immune protein
immune
protein
Prior art date
Application number
IS5375A
Other languages
Icelandic (is)
Inventor
Tschopp Jurg
Original Assignee
Apotech Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Apotech Sa filed Critical Apotech Sa
Publication of IS5375A publication Critical patent/IS5375A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Transplantation (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
IS5375A 1997-09-12 2000-02-11 KAY-Innovative Immune Protein IS5375A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5878697P 1997-09-12 1997-09-12
PCT/US1998/019037 WO1999012964A2 (en) 1997-09-12 1998-09-11 Kay - a novel immune system protein

Publications (1)

Publication Number Publication Date
IS5375A true IS5375A (en) 2000-02-11

Family

ID=22018915

Family Applications (1)

Application Number Title Priority Date Filing Date
IS5375A IS5375A (en) 1997-09-12 2000-02-11 KAY-Innovative Immune Protein

Country Status (17)

Country Link
EP (1) EP1012270A2 (en)
JP (1) JP2001515711A (en)
KR (1) KR20010023892A (en)
CN (1) CN1269832A (en)
AU (1) AU9315298A (en)
BR (1) BR9812433A (en)
CA (1) CA2303424A1 (en)
EA (1) EA200000311A1 (en)
EE (1) EE200000148A (en)
HU (1) HUP0004034A3 (en)
IL (1) IL134480A0 (en)
IS (1) IS5375A (en)
NO (1) NO20001240L (en)
PL (1) PL339740A1 (en)
SK (1) SK3532000A3 (en)
TR (1) TR200000654T2 (en)
WO (1) WO1999012964A2 (en)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6812327B1 (en) 1996-10-25 2004-11-02 Human Genome Sciences, Inc. Neutrokine-alpha polypeptides
CA2310987A1 (en) * 1997-11-26 1999-06-03 Eli Lilly And Company Tnf ligand family gene
US6297367B1 (en) 1997-12-30 2001-10-02 Chiron Corporation Polynucleotide encoding TNFL1
AU2093499A (en) * 1997-12-30 1999-07-19 Chiron Corporation Members of tnf and tnfr families
WO2001060397A1 (en) 2000-02-16 2001-08-23 Genentech, Inc. Uses of agonists and antagonists to modulate activity of tnf-related molecules
US7488590B2 (en) 1998-10-23 2009-02-10 Amgen Inc. Modified peptides as therapeutic agents
GB9828628D0 (en) 1998-12-23 1999-02-17 Glaxo Group Ltd Novel ligand
US7833529B1 (en) 1999-01-07 2010-11-16 Zymogenetics, Inc. Methods for inhibiting B lymphocyte proliferation with soluble ztnf4 receptor
US20030095967A1 (en) 1999-01-25 2003-05-22 Mackay Fabienne BAFF, inhibitors thereof and their use in the modulation of B-cell response and treatment of autoimmune disorders
CZ299819B6 (en) 1999-01-25 2008-12-03 Biogen Idec Ma Inc. Pharmaceutical compositions containing antibodies specific for soluble BAFF
US6475986B1 (en) 1999-02-02 2002-11-05 Research Development Foundation Uses of THANK, a TNF homologue that activates apoptosis
EP1860190A3 (en) * 1999-02-23 2008-03-12 Human Genome Sciences, Inc. Neutrokine-alpha and neutrokine-alpha splice variants
US20030022233A1 (en) 1999-04-30 2003-01-30 Raymond G. Goodwin Methods of use of the taci/taci-l interaction
WO2000068378A1 (en) * 1999-05-06 2000-11-16 National Jewish Medical And Research Center Tall-1 nucleic acid molecules, proteins, receptors and methods of use thereof
HK1043608B (en) * 1999-08-17 2007-12-07 Biogen Ma Inc. Baff receptor (bcma), an immunoregulatory agent
UA74798C2 (en) * 1999-10-06 2006-02-15 Байоджен Айдек Ма Інк. Method for treating cancer in mammals using polypeptide interfering with interaction between april and its receptors
EP1259544B1 (en) 2000-02-11 2011-08-24 Biogen Idec MA Inc. Heterologous polypeptide of the tnf family
AU2001263114A1 (en) 2000-05-12 2001-11-26 Amgen Inc Methods and compositions of matter concerning april/g70, bcma, blys/agp-3, and taci
AU2001268427B2 (en) 2000-06-16 2007-03-29 Glaxosmithkline Intellectual Property Limited Antibodies that immunospecifically bind to blys
US7220840B2 (en) 2000-06-16 2007-05-22 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator protein
EP1309718A4 (en) * 2000-08-15 2004-08-25 Human Genome Sciences Inc NEUTROKIN-ALPHA AND SPLICE VARIANTS FROM NEUTROKIN-ALPHA
AU2001288301A1 (en) 2000-08-18 2002-03-04 Human Genome Sciences, Inc. Binding polypeptides and methods based thereon
UA83458C2 (en) 2000-09-18 2008-07-25 Байоджен Айдек Ма Інк. The isolated polypeptide baff-r (the receptor of the factor of activation of b-cells of the family tnf)
HU229910B1 (en) 2001-05-11 2014-12-29 Amgen Inc Thousand Oaks Peptides and related molecules that bind to tall-1
AR035119A1 (en) 2001-08-16 2004-04-14 Lilly Co Eli ANTI-HTNFSF13B HUMAN ANTI-BODIES
EP1608730B1 (en) 2003-03-28 2013-11-06 Biogen Idec MA Inc. Truncated baff receptors
ES2537738T3 (en) 2003-06-05 2015-06-11 Genentech, Inc. Combination therapy for B cell disorders
WO2005042009A1 (en) 2003-10-20 2005-05-12 Biogen Idec Ma Inc. Therapeutic regimens for baff antagonists
WO2005075511A1 (en) * 2004-01-29 2005-08-18 Genentech, Inc. Variants of the extracellular domain of bcma and uses thereof
CN101087807A (en) 2004-10-05 2007-12-12 健泰科生物技术公司 Method for treating vasculitis
NZ583905A (en) 2004-10-13 2011-12-22 Univ Washington Use of BAFF to Treat Sepsis
AU2005318086B2 (en) 2004-12-23 2011-07-07 Merck Serono Sa BCMA polypeptides and uses thereof
KR20080056714A (en) 2005-08-09 2008-06-23 지모제넥틱스, 인코포레이티드 How to Treat VIII-Cell Malignancies Using TACI-IGg Fusion Molecules
US8808696B2 (en) 2005-08-09 2014-08-19 Ares Trading S.A. Methods for the treatment and prevention of abnormal cell proliferation using TACI-fusion molecules
US9168286B2 (en) 2005-10-13 2015-10-27 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive disease
MY149159A (en) 2005-11-15 2013-07-31 Hoffmann La Roche Method for treating joint damage
CA2629306A1 (en) 2005-11-23 2007-05-31 Genentech, Inc. Methods and compositions related to b cell assays
WO2007123765A2 (en) 2006-03-31 2007-11-01 Human Genome Sciences Inc. Neutrokine-alpha and neutrokine-alpha splice variant
WO2007134326A2 (en) 2006-05-15 2007-11-22 Ares Trading S.A. Methods for treating autoimmune diseases using a taci-ig fusion molecule
WO2010075249A2 (en) 2008-12-22 2010-07-01 Genentech, Inc. A method for treating rheumatoid arthritis with b-cell antagonists
JP5996429B2 (en) 2009-09-03 2016-09-21 ジェネンテック， インコーポレイテッド Method for treatment, diagnosis and monitoring of rheumatoid arthritis
RU2013140975A (en) 2011-02-28 2015-04-10 Дженентек, Инк. BIOLOGICAL MARKERS AND METHODS FOR PREDICTING SUSCEPTIBILITY TO B-CELL ANTAGONISTS
JP6636803B2 (en) 2013-02-05 2020-01-29 エンクマフ エスアーエールエル Method for selection of antibodies to BCMA
US9458246B2 (en) 2013-03-13 2016-10-04 Amgen Inc. Proteins specific for BAFF and B7RP1
PH12022550138A1 (en) 2013-03-13 2023-03-06 Amgen Inc Proteins specific for baff and b7rp1 and uses thereof
JP6577958B2 (en) 2014-04-11 2019-09-18 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Spiro [3H-indole-3,2'-pyrrolidin] -2 (1H) -one derivatives and their use as MDM2-p53 inhibitors

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5891679A (en) * 1993-02-03 1999-04-06 N.V. Innogenetics S.A. TNF-alpha muteins and a process for preparing them
WO1996040774A1 (en) * 1995-06-07 1996-12-19 Biogen, Inc. Complexes of modified lymphotoxins as pharmaceutical preparations
NZ334309A (en) * 1996-10-25 2000-08-25 Human Genome Sciences Inc Neutrokine alpha protein, a member of the TNF family, and its use in treating and/or detecting immune disorders
AU5705898A (en) * 1996-12-17 1998-07-15 Schering Corporation Mammalian cell surface antigens; related reagents
CA2232743A1 (en) * 1997-04-02 1998-10-02 Smithkline Beecham Corporation A tnf homologue, tl5

Also Published As

Publication number Publication date
HUP0004034A3 (en) 2002-08-28
JP2001515711A (en) 2001-09-25
EP1012270A2 (en) 2000-06-28
CN1269832A (en) 2000-10-11
NO20001240L (en) 2000-05-10
BR9812433A (en) 2000-09-26
EA200000311A1 (en) 2000-10-30
NO20001240D0 (en) 2000-03-09
TR200000654T2 (en) 2000-07-21
AU9315298A (en) 1999-03-29
WO1999012964A3 (en) 1999-05-27
EE200000148A (en) 2001-02-15
KR20010023892A (en) 2001-03-26
PL339740A1 (en) 2001-01-02
HUP0004034A2 (en) 2001-03-28
WO1999012964A2 (en) 1999-03-18
SK3532000A3 (en) 2001-12-03
IL134480A0 (en) 2001-04-30
CA2303424A1 (en) 1999-03-18

Similar Documents

Publication Publication Date Title
NO20001240D0 (en) Kay-A immune system protein
DK0921796T3 (en) Tetrahydrolipstatin-containing preparations
DE69839603D1 (en) ORNAMENTAL PROTEINS
NO20002990L (en) New surface protein
ID24289A (en) BENZOTIAZOL INHIBITOR-INHIBITOR TERININ CINASE PROTEIN
ATE285788T1 (en) ACTIVATED PROTEIN C FORMULATIONS
NO983364D0 (en) Consensus Proteins
DE69826554D1 (en) armchair
NO2010013I1 (en) Recombinant FSH-CTP
DE69805844D1 (en) IFNNAR / IFN COMPLEX
DE69812435T2 (en) CONVEYOR
NO20001507L (en) Lastearmopphengningssystem
DE59801983D1 (en) CONVEYOR
DE69817583D1 (en) CONVEYOR
EP1018551A4 (en) MEGSINE PROTEIN
DE69836069D1 (en) triac
EP1012262A4 (en) HUMAN FREZZELED-LIKE PROTEIN
ATE295417T1 (en) ANGIOSTATIN-BINDING PROTEIN
TR199701666A3 (en) Proteins
DK0862850T3 (en) combine
ATA112597A (en) SNOWBOARD - BINDING
DE69830081D1 (en) connecting piece
EP0949331A4 (en) ESTABLISHED MICROGLIOCYTE
PT1015447E (en) DERIVED PIPERIDYLMETHYLLOXAZOLIDINONE
ID23663A (en) KAPROLAKTAM PREPARATION